Royds Withy King helps Oxford Genetics secure a further £3.0m syndicated investment
OXGENE™ combines precision engineering, biology, robotics and bioinformatics to accelerate the design, discovery and manufacture of new biologics. Working across the fields of gene therapy, gene editing and antibody therapeutics, OXGENE™ has worked with global partners including Abcam plc for the delivery of over 1,000 CRISPR engineered cell lines, Artios Pharma, who are developing breakthrough cancer treatments, and The Native Antigen Company (also backed by Mercia Asset Management) to accelerate the production of COVID‐19 antigens.
Iain Butler, Corporate Partner, who led the Royds Withy King team on the deal said “We are very proud to continue to support the fantastic work done by Oxford based businesses in the life sciences community who are working like OXGENE™ ‘at the edge of impossible’ to bring innovative technologies to market.”
Whilst COVID-19 presents a significant challenge for private equity and venture capital, the Corporate team at Royds Withy King have lots of experience advising technology businesses from spin-out to exit and believe there remains a high level of investor confidence in quality, high growth investments which deliver long term value.
Iain adds: “We enjoy backing entrepreneurial management teams who have the drive and ambition to innovate and we’re pleased to see great Oxfordshire businesses at the leading edge of the fight against the COVID-19 pandemic.
Following our recent strategic hires, our Corporate teams continue to complete investment and M&A transactions in the current market and we remain committed to supporting entrepreneurs, founders and management teams looking at options for future funding.”